Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Allogeneic bone marrow transplantation Tabbara IASouth Med J 1996[Sep]; 89 (9): 857-68Allogeneic bone marrow transplantation (BMT) after high-dose, marrow-ablative chemoradiotherapy has been established as the treatment of choice for various hematologic, neoplastic, and congenital disorders. The most common type of marrow graft is an allogeneic one from a sibling donor who has compatible human leukocyte antigen (HLA). Only 30% of patients requiring allogeneic BMT have an HLA-compatible sibling donor. Over the past few years, marrows from unrelated HLA-compatible donors have been used with increasing frequency and promising outcome in certain hematologic malignancies. Despite the morbidity and mortality associated with this treatment modality, allogeneic BMT may provide a 20% to 90% chance of long-term, disease-free survival to patients with a wide variety of neoplastic and abnormal marrow disorders.|Bone Marrow Diseases/therapy[MESH]|Bone Marrow Purging/methods[MESH]|Bone Marrow Transplantation/adverse effects/*methods[MESH]|Bone Marrow/drug effects/radiation effects[MESH]|Disease-Free Survival[MESH]|HLA Antigens/genetics[MESH]|Hematologic Diseases/therapy[MESH]|Histocompatibility[MESH]|Humans[MESH]|Neoplasms/therapy[MESH]|Transplantation, Homologous[MESH]|Treatment Outcome[MESH] |
